The following claims are presented for examination:

- (previously presented) A drug delivery device comprising: a drug; and a vascular implant having a blood-contacting surface and a helical formation on the blood contacting surface, the helical formation being capable of inducing helical flow of blood flowing past the helical formation, and the drug being releasably associated with the helical formation of the vascular implant.
- 2. (original) A drug delivery device according to claim 1 wherein the drug is mixed into the material from which the helical formation is made.
- **3.** (previously presented) A drug delivery device according to claim 1 wherein the drug is coated onto the surface of the helical formation.
- **4.** (previously presented) A drug delivery device according to claim 1 wherein the helical formation is made from a polymer.

## Claims 5-16 (canceled)

- 17. (previously presented) A drug delivery device according to claim 4 wherein the polymer is a polymer foam.
- **18.** (previously presented) A drug delivery device according to claim 4 wherein the polymer is selected from the group consisting of: polyamide, polyester, and polyurethane.
- **19.** (previously presented) A drug delivery device according to claim 4 wherein the drug is bound onto the cellular structure of the polymer.
- 20. (previously presented) A drug delivery device according to claim 1 wherein the drug is selected from the group consisting of: an anticoagulant, an antiplatelet agent, an angiogenesis inhibitor, a cyclooxygenase inhibitor, a gene therapy agent, and a mixture of two or more of said drugs.
- 21. (previously presented) A drug delivery device according to claim 1 wherein the vascular implant is selected from the group consisting of: an intravascular stent insert, a vascular graft, and a stent graft.
- 22. (previously presented) A drug delivery device according to claim 21 wherein the vascular implant is a stent and the drug delivery device further comprises a sleeve positioned surrounding and/or within the stent.

- 23. (previously presented) A drug delivery device according to claim 22 wherein the sleeve is made from expanded PTFE.
- 24. (previously presented) A drug delivery device according to daim 1 wherein the drug is also releasably associated with the blood-contacting surface of the vascular implant.
- **25.** (previously presented) A drug delivery device according to claim 1 wherein at least one further drug is provided releasably associated with the helical formation.
- **26.** (previously presented) A drug delivery device according to daim 1 wherein the helix angle of the helical formation is between 8° and 20°.
- **27.** (previously presented) A drug delivery device according to claim 1 wherein the helical formation comprises at least one fin.
- **28.** (previously presented) A drug delivery device according to claim 27 wherein the at least one fin has the shape of a right-angle triangle in cross-section.
- **29.** (previously presented) A drug delivery device according to claim 27 wherein the at least one fin has the shape of an isosceles triangle in cross-section.
- **30.** (previously presented) A drug delivery device according to claim 27 where the at least one fin has the shape of a bell in cross-section.
- **31.** (previously presented) A drug delivery device according to claim 30 where the at least one fin has the shape of an asymmetric bell in cross-section.
- **32.** (previously presented) A drug delivery device according to claim 1 wherein the helical formation comprises a groove.